Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

@article{Manns2001PeginterferonAP,
  title={Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial},
  author={M. Manns and J. McHutchison and S. Gordon and V. Rustgi and M. Shiffman and R. Reindollar and Z. Goodman and K. Koury and M. Ling and J. Albrecht},
  journal={The Lancet},
  year={2001},
  volume={358},
  pages={958-965}
}
BACKGROUND A sustained virological response (SVR) rate of 41% has been achieved with interferon alfa-2b plus ribavirin therapy of chronic hepatitis C. In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin. [...] Key MethodMETHODS 1530 patients with chronic hepatitis C were assigned interferon alfa-2b (3 MU subcutaneously three times per week) plus ribavirin 1000-1200 mg/day orally, peginterferon alfa-2b 1.5 microg/kg each week plus 800 mg/day…Expand
Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
TLDR
In patients with chronic HCV infection, peginterferon alfa-2a plus ribavirin produced a significantly higher sustained virological response (SVR) rate than pegin terferonAlfa- 2b plus Ribavirin. Expand
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
TLDR
In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone. Expand
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
TLDR
The marked discrepancy in the rates of sustained virologic response between HCV genotypes indicates that strategies are needed to improve the outcome in persons infected withHCV genotype 1. Expand
Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial.
TLDR
For patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus ribvirin and produced significant improvements in the rate of sustained viral reduction. Expand
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
TLDR
Combination therapy with an induction dose of PEG-IFN was a more effective and better tolerated treatment for naïve patients with genotype 1 than combination therapy with high dose standard IFN, and in patients aged less than 50 years with mild fibrosis this schedule achieves a very high rate of SVR. Expand
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
TLDR
PEG-INF +RBV was significantly more effective than INF + RBV for the treatment of chronic hepatitis C in HIV co-infected patients, mainly of genotype 1 or 4. Expand
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
TLDR
Investigating this schedule in the era of pegylated interferon-alpha plus ribavirin for chronically infected patients with a low baseline HCV-RNA concentration found it may be treated for 24 weeks without compromising sustained virologic response rates. Expand
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
TLDR
Among patients infected with both HIV and HCV, the combination of peginterferon alfa-2a plus ribavirin was significantly more effective than either interferonalfa- 2a plus Ribavirin or pegin terferonAlfa-3a monotherapy. Expand
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
TLDR
These results in a large patient cohort demonstrate that it is possible to cure a proportion of previous non-responders and relapsers by retreating with peginterferon alfa-2a (40KD) plus ribavirin. Expand
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
TLDR
Treatment with peginterferon and ribavirin for 16 weeks in patients infected with HCV genotype 2 or 3 results in a lower overall sustained virologic response rate than treatment with the standard 24-week regimen. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
TLDR
AnInterferon α2b plus ribavirin combination is more effective than 48 weeks of interferonα2b monotherapy and has an acceptable safety profile and patients with few favourable factors benefit more from extending the duration of combination therapy to 48 weeks. Expand
Peginterferon alfa-2a in patients with chronic hepatitis C.
TLDR
In patients with chronic hepatitis C, a regimen of peginterferon alfa-2a given once weekly is more effective than a regimen that has sustained absorption, a slower rate of clearance, and a longer half-life than unmodified interferonAlfa- 2a. Expand
PEGINTERFERON ALFA-2 a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS
A BSTRACT Background Chronic hepatitis C virus (HCV) infection in patients with cirrhosis is difficult to treat. In patients with chronic hepatitis C but without cirrhosis, once-weekly administrationExpand
A Dose‐Ranging Study of Pegylated Interferon Alfa‐2b and Ribavirin in Chronic Hepatitis C
TLDR
Combined PEG‐Intron/ribavirin showed dose‐related synergistic anti‐HCV effects, which were numerically superior to those obtained with PEG-Intron monotherapy. Expand
Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
TLDR
Results indicate that testing for HCV RNA at week 12 to identify nonresponders and then discontinuing their treatment is practical, cost‐efficient and beneficial both to patients and to third‐party payers. Expand
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.
TLDR
Data support the hypothesis that maintenance interferon may prevent histological progression of chronic HCV in patients who remain viremic and stop treatment was associated with an increase in serum ALT, log HCV-RNA, and hepatic inflammation back to baseline. Expand
A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C
TLDR
PegIntron alfa‐2b maintained the clinical efficacy of interferon alfa'2b while preserving its safety profile and increased virologic response rates after treatment and after follow‐up, as compared with interferons alfa'; however, the higher rate of virolic response during treatment with 1.5 μg/kg peginterferonAlfa‐ 2b in patients infected with genotype 1 and high viral levels warrants further evaluation. Expand
Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
TLDR
The results indicate that chronic HCV patients with high pretreatment HCV RNA titers showed greater discordance between sustained ALT andHCV RNA responses compared with patients with low pret treatment HCVRNA titers and that measurement of HCVs RNA should be included in the assessment of response to IFN therapy in chronic hepatitis C patients. Expand
Liver transplantation for chronic viral hepatitis.
A better understanding of the mechanism of viral replication and of viral transmission has led to improved results with OLTx for patients with end-stage liver disease caused by viral hepatitis.Expand
Liver transplantation for chronic viral hepatitis.
TLDR
Liver transplantation remains a problem for end stage liver disease due to chronic viral hepatitis in contrast to the success with fulminant hepatitis B, D and C in which recurrence of viraemia is relatively rare, and there are no firm recommendations that can be given to prevent recurrence. Expand
...
1
2
3
4
...